differentiated antibiotics

Cempra, Inc. to Present at Three Investor Conferences

CHAPEL HILL, N.C., Aug. 27, 2014 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP) today announced that Prabhavathi Fernandes, Ph.D., chief executive officer of Cempra, will present at three upcoming investor conferences.


Cempra Initiates Phase 3 Clinical Trial in Patients with Uncomplicated Gonorrhea Infection

CHAPEL HILL, N.C., Aug. 12, 2014 -- Cempra, Inc., (Nasdaq: CEMP) today announced the initiation of a Phase 3 clinical trial, called Solitaire-U, of a single 1000 mg dose of oral solithromycin in patients with uncomplicated Neisseria gonorrhea and chlamydia infections.